Gilead's Harvoni beats Sovaldi, AbbVie's Viekira Pak in hep C drug safety: Advera

Drug safety numbers have been weighing in Gilead's ($GILD) favor lately, with recent analyses showing that its hep C superstars Harvoni and Sovaldi are safer than AbbVie's ($ABBV) rival med Viekira Pak. But Harvoni could be the safest option of the three, turning up the fewest reports of serious side effects, according to a new report by healthcare informatics firm Advera Health Analytics. More from FiercePharma

Suggested Articles

Eli Lilly bought full-page ads in more than a dozen newspapers in the U.S. to let people with diabetes who use Lilly drugs to know help is available.

Only months after a game-changing new approval for Vascepa, Amarin has lost a key fight over its patents—and now it's scrambling to respond.

Move over, Roche. There’s a new small cell lung cancer therapy on the scene, and it belongs to AstraZeneca.